awmsg logo



sildenafil citrate (Revatio®)


Reference No. 273

Publication date:
12/08/2010


Appraisal information

sildenafil citrate (Revatio®) 20 mg film-coated tablet


Company: Pfizer Ltd
BNF category: Cardiovascular system
NMG meeting date: 19/05/2010
AWMSG meeting date: 23/06/2010
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1010
Ministerial ratification: 03/08/2010

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Sildenafil (Revatio®) is recommended, within its current licensed indication, as an option for use within NHS Wales for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity. AWMSG recommends that its use be restricted to a physician experienced in the treatment of PAH in association with a National Commissioning Group designated expert centre. AWMSG is of the opinion that sildenafil (Revatio®) is not suitable for shared care between primary and secondary care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download